Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Language
Publication year range
1.
Angiology ; 75(4): 331-339, 2024 Apr.
Article in English | MEDLINE | ID: mdl-36710003

ABSTRACT

There is no consensus regarding mitral valve management during surgical ventricular restoration (SVR) for ischemic cardiomyopathy. We compared the impact of SVR with mitral valve repair (MVr) vs replacement (MVR) on postoperative outcomes and long-term survival in ischemic cardiomyopathy and mitral regurgitation patients. This study included 112 patients who underwent SVR from 2009 to 2018 with MVr (n = 75) or MVR (n = 37). Patients who had MVR had higher Euro SCORE II, dyspnea class, a lower ejection fraction, higher pulmonary artery systolic pressure, higher grade of preoperative mitral and tricuspid regurgitation, and higher end-diastolic and end-systolic diameters. Intra-aortic balloon pump was more commonly used in patients with MVR. Hospital mortality occurred in 7 (9.33%) patients in the MVr group vs 3 (8.11%) in the MVR group (P > .99). Freedom from rehospitalization at 1, 5, and 7 years was 87%, 76%, and 70% in the MVr group and 83%, 61%, and 52% in the MVR group (P = .191). Survival at 1, 5, and 7 years was 88%, 78%, and 74% in the MVr group and 88%, 56%, and 56% in the MVR group (P = .027). Adjusted survival did not differ between groups.MVr or MVR are valid options in patients undergoing SVR, with good long-term outcomes.


Subject(s)
Cardiomyopathies , Heart Valve Prosthesis Implantation , Mitral Valve Insufficiency , Myocardial Ischemia , Humans , Mitral Valve/surgery , Heart Valve Prosthesis Implantation/adverse effects , Treatment Outcome , Myocardial Ischemia/complications , Myocardial Ischemia/surgery , Mitral Valve Insufficiency/surgery , Cardiomyopathies/surgery
2.
Drug Deliv Transl Res ; 14(4): 1077-1092, 2024 Apr.
Article in English | MEDLINE | ID: mdl-37957473

ABSTRACT

The growing interest in employing nano-sized pharmaceutical formulations in veterinary medicine has prompted the exploration of the novel nanocarriers' ability to augment the therapeutic outcome. In this study, we harnessed niosomes, spherical nanocarriers formed through non-ionic surfactant self-assembly, to enhance the therapeutic efficacy of the broad-spectrum antibiotic florfenicol. Pre-formulation studies were conducted to identify the optimal parameters for preparing florfenicol-loaded niosomes (FLNs). These studies revealed that the formulation that consisted of Span 60, cholesterol, and dihexadecyl phosphate (DDP) at a molar ratio of 1:1:0.1 exhibited the highest entrapment efficiency (%EE) and uniform size distribution. In vitro antibacterial testing demonstrated the niosomal capacity to significantly reduce florfenicol minimum inhibitory concentration (MIC) against E. coli and S. aureus. Pharmacokinetic profiles of free florfenicol and FLN were assessed following oral administration of 30 mg florfenicol/kg body weight to healthy or E. coli-infected chickens. FLN exhibited a substantially higher maximum plasma concentration (Cmax) of florfenicol compared to free florfenicol. Furthermore, FLN showed significantly higher area under the curve (AUC0-t) than free florfenicol as revealed from the relative bioavailability studies. Lethal dose (LD) 50 values for both free florfenicol and FLN exceeded 5 g/kg of body weight, indicating high safety profile. Assessment of mortality protection in mice against lethal E. coli infections showed the significantly higher capability of FLN to improve the survival rate (75%) than free florfenicol (25%). Collectively, these findings demonstrate the niosomal ability to improve the oral bioavailability as well as the antibacterial activity of the incorporated veterinary antibiotic florfenicol.


Subject(s)
Escherichia coli , Liposomes , Thiamphenicol/analogs & derivatives , Animals , Mice , Staphylococcus aureus , Chickens , Anti-Bacterial Agents/pharmacology , Body Weight
3.
J Chem Neuroanat ; 128: 102234, 2023 03.
Article in English | MEDLINE | ID: mdl-36640914

ABSTRACT

Alzheimer's disease (AD) is one of the neurodegenerative illnesses that impair individual life & increase the demand for caregivers with no available curative medication right now. Therefore, there is a growing concern about employing herbal medicine to limit AD progression & improve patients' life quality, thus potentiating its add-on therapy. In addition, herbs are cost-effective & accessible with nearly no side effects. In the same vein, our study aimed to investigate the potency of Echinacea purpurea (EP) flower extracts to ameliorate the neurodegenerative effect of Aluminum chloride (AlCl3) in a rat model. Moreover, mechanistic studies, including impact on the cholinesterase activity, redox status, inflammatory mediators, behavior performance, glucose level & histopathology, were carried on. Our results showed that 250 mg/kg of Aqueous (AQ) & Alcoholic (AL) extracts of EP inhibited cholinesterase, restored oxidative balance, down-regulated IL-6 & TNF-α cytokines & improved behavior performance in vivo that was reflected in the brain picture by decreasing neuronal degeneration & amyloid plaques in cerebral cortex & hippocampus. The potency of both extracts was compared to reference drugs & AlCl3 positive control group. The AQ extract showed greater potency against COX-1, COX-2 & α-amylase in vitro, while the AL extract was more potent against cholinesterase in vitro, inflammatory cytokines, behavior & pathological improvement in vivo. Conclusively EP overcame AlCl3-induced neurobehavioral toxicity in the rat model via different pathways, which support its regular administration to postpone progressive neural damage in AD patients.


Subject(s)
Alzheimer Disease , Echinacea , Animals , Rats , Aluminum Chloride , Alzheimer Disease/metabolism , Cholinesterases , Cytokines/metabolism , Echinacea/metabolism , Plant Extracts/pharmacology
4.
Rev. bras. cir. cardiovasc ; 36(1): 10-17, Jan.-Feb. 2021. tab, graf
Article in English | LILACS | ID: biblio-1155793

ABSTRACT

Abstract Introduction: There are scarce data comparing different mechanical valves in the aortic position. The objective of this study was to compare the early hemodynamic changes after aortic valve replacement between ATS, Bicarbon, and On-X mechanical valves. Methods: We included 99 patients who underwent aortic valve replacement with mechanical valves between 2017 and 2019. Three types of mechanical valves were used, On-X valve (n=45), ATS AP360 (n=32), and Bicarbon (n=22). The mean prosthetic valve gradient was measured postoperatively and after six months. Results: Preoperative data were comparable between groups, and there were no differences in preoperative echocardiographic data. Pre-discharge echocardiography showed no difference between groups in the ejection fraction (P=0.748), end-systolic (P=0.764) and end-diastolic (P=0.723) diameters, left ventricular mass index (P=0.348), aortic prosthetic mean pressure gradient (P=0.454), and indexed aortic prosthetic orifice area (P=0.576). There was no difference in the postoperative aortic prosthetic mean pressure gradient between groups when stratified by valve size. The changes in the aortic prosthetic mean pressure gradient of the intraoperative period, at pre-discharge, and at six months were comparable between the three prostheses (P=0.08). Multivariable regression analysis revealed that female gender (beta coefficient -0.242, P=0.027), body surface area (beta coefficient 0.334, P<0.001), and aortic prosthetic size (beta coefficient -0.547, P<0.001), but not the prosthesis type, were independent predictors of postoperative aortic prosthetic mean pressure gradient. Conclusion: The three bileaflet mechanical aortic prostheses (On-X, Bicarbon, and ATS) provide satisfactory early hemodynamics, which are comparable between the three valve types and among different valve sizes.


Subject(s)
Humans , Male , Female , Aortic Valve Stenosis/surgery , Heart Valve Prosthesis , Aortic Valve/surgery , Aortic Valve/diagnostic imaging , Prosthesis Design , Echocardiography , Echocardiography, Doppler , Hemodynamics
5.
Braz J Cardiovasc Surg ; 36(1): 10-17, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-33355803

ABSTRACT

INTRODUCTION: There are scarce data comparing different mechanical valves in the aortic position. The objective of this study was to compare the early hemodynamic changes after aortic valve replacement between ATS, Bicarbon, and On-X mechanical valves. METHODS: We included 99 patients who underwent aortic valve replacement with mechanical valves between 2017 and 2019. Three types of mechanical valves were used, On-X valve (n=45), ATS AP360 (n=32), and Bicarbon (n=22). The mean prosthetic valve gradient was measured postoperatively and after six months. RESULTS: Preoperative data were comparable between groups, and there were no differences in preoperative echocardiographic data. Pre-discharge echocardiography showed no difference between groups in the ejection fraction (P=0.748), end-systolic (P=0.764) and end-diastolic (P=0.723) diameters, left ventricular mass index (P=0.348), aortic prosthetic mean pressure gradient (P=0.454), and indexed aortic prosthetic orifice area (P=0.576). There was no difference in the postoperative aortic prosthetic mean pressure gradient between groups when stratified by valve size. The changes in the aortic prosthetic mean pressure gradient of the intraoperative period, at pre-discharge, and at six months were comparable between the three prostheses (P=0.08). Multivariable regression analysis revealed that female gender (beta coefficient -0.242, P=0.027), body surface area (beta coefficient 0.334, P<0.001), and aortic prosthetic size (beta coefficient -0.547, P<0.001), but not the prosthesis type, were independent predictors of postoperative aortic prosthetic mean pressure gradient. CONCLUSION: The three bileaflet mechanical aortic prostheses (On-X, Bicarbon, and ATS) provide satisfactory early hemodynamics, which are comparable between the three valve types and among different valve sizes.


Subject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis , Aortic Valve/diagnostic imaging , Aortic Valve/surgery , Aortic Valve Stenosis/surgery , Echocardiography , Echocardiography, Doppler , Female , Hemodynamics , Humans , Male , Prosthesis Design
6.
Food Chem Toxicol ; 135: 111055, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31838190

ABSTRACT

This study explored the camel milk (CM) efficacy to ameliorate the fenpropathrin (FNP) induced neurotoxic impacts in rats. Six groups were orally administered physiological saline, corn oil, CM (2ml/rat/day), FNP (15 mg/kg bw daily for 60 days), CM/FNP (protective) or FNP + CM (therapeutic). Sensorimotor functions, memory, exploratory, and locomotor activities were assessed. The levels of dopamine (DOPA) neurotransmitter, acetylcholinesterase (AChE) enzyme, oxidative stress, and inflammatory markers were determined. Brain histopathology and apoptotic markers immunohistochemical detection were performed. The results revealed that FNP exposure resulted in deficit sensorimotor functions, impaired memory, and less exploration. DOPA and AChE Levels were significantly reduced. FNP exposure increased nitric oxide, malondialdehyde, myeloperoxidase, Caspase-3, and tumor necrosis factor-alpha levels but interleukin 10, total antioxidant capacity, and Bcl-2 levels were declined. Also, FNP exposure induced obvious encephalopathy. Additionally, neurodegenerative changes were seen in the hippocampi of FNP-treated rats. FNP Exposure induced a significant decrease of Bcl-2 immunolabelling but Caspase-3 immunoexpression was increased in cerebral cortices and hippocampus tissues. CM significantly counteracted the FNP injurious impacts, especially when used as a prophylactic routine than a therapeutic one. Conclusively, these findings confirmed that CM could be a biologically effective protective agent against FNP induced neurobehavioral aberrations and neurotoxic impacts.


Subject(s)
Apoptosis , Brain/drug effects , Milk , Oxidative Stress , Pyrethrins/toxicity , Animals , Behavior, Animal/drug effects , Brain/metabolism , Brain/pathology , Camelus , Dose-Response Relationship, Drug , Inflammation/chemically induced , Male , Memory/drug effects , Neurotoxicity Syndromes , Pyrethrins/administration & dosage , Rats , Rats, Sprague-Dawley
7.
Parasitol Res ; 107(1): 17-25, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20349194

ABSTRACT

There is a considerable interest in developing new anthelmintic drugs including those from medicinal plants due to increasing evidence of parasitic resistance against present anthelmintic drugs and decreasing activity against encapsulated larval stages of parasites. This study was carried out to assess, for the first time, the effectiveness of methanolic extract of Balanites aegyptiaca (BAE) fruits against different stages (pre-adult, migrating larvae, and encysted larvae) of Trichinella spiralis in rats compared with commonly used anthelmintic albendazole. Oral administration of BAE at a dose of 1,000 mg/kg b.wt. for five successive days throughout the parasite life cycle led to a marked reduction of migrating and encysted larval rate by 81.7% and 61.7%, respectively, in the muscular tissue. This treatment was less effective against adults in the gut (47.8%). Albendazole treatment at a dose of 10 mg/kg b.wt. for five successive days resulted in a marked eradication of T. spiralis adult worms (94.4%) and less reduction of migrating and encysted larval infections of skeletal muscles (62.2% and 26.4%, respectively). BAE-treated groups showed marked decreases in serum-glucose levels, triglyceride concentrations, aspartate aminotransferase (AST), creatinine phosphokinase (CPK) activities, and lipid peroxide products (malondialdehyde, MDA) as well as an increase in glutathione level in both serum and muscular tissue compared to albendazole-treated- and infected-untreated groups. This result was confirmed by few numbers of living- and dead-encysted larvae and less destruction of the diaphragm and skeletal muscle tissues in BAE-treated groups compared to other treated groups. It can be concluded that the methanolic extract of B. aegyptiaca fruits has high effectiveness against parenteral stages of T. spiralis than albendazole. Albendazole is more effective against enteral stage of T. spiralis than the extract.


Subject(s)
Anthelmintics/administration & dosage , Anthelmintics/isolation & purification , Balanites/chemistry , Plant Extracts/administration & dosage , Plant Extracts/isolation & purification , Trichinella spiralis/drug effects , Administration, Oral , Albendazole/administration & dosage , Animals , Anthelmintics/adverse effects , Blood Chemical Analysis , Diaphragm/parasitology , Fruit/chemistry , Histocytochemistry , Microscopy , Muscle, Skeletal/parasitology , Plant Extracts/adverse effects , Rats , Rats, Sprague-Dawley , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...